Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
Control-IQ System Demonstrates Ability in Children 2-6 Years Old in PEDAP Trial
March 16th 2023A 13-week trial examining use of the Control-IQ closed-loop insulin delivery system in children aged 2-6 years, results of PEDAP indicate use of the closed-loop system was associated with a 3 hour per day increase in time in range relative to standard care.
Read More
Increased BMI in Childhood Increases Hypertension Risk as an Adult
March 14th 2023An analysis of more than 800,000 children with more than 3.5 million person-years of follow-up indicate those in the upper range of average BMI had a 26% greater risk of developing hypertension, with each per unit increase in BMI associated with a 4% increase in risk of hypertension.
Read More
Viet Le, PA-C: Value of Disproportionate CAC vs Total CAC for Predicting MACE
March 10th 2023New research from Intermountain Healthcare presented at ACC 2023 examines the prognostic value of disproportionate CAC scores for 1 or more vessels relative to the value of total CAC score for predicting major adverse cardiovascular events.
Read More
Experts' Perspective: Top Cardiology News from ACC 23
March 10th 2023With ACC 2023 in the rearview, the HCPLive editorial team compiled perspectives on the meeting’s top piece of news from half a dozen clinicians specializing in various subspecialties across the spectrum of cardiovascular care.
Read More
FDA Accepts sNDA for Empagliflozin in Children with Type 2 Diabetes Aged 10 & Older
March 8th 2023If approved, Boehringer Ingelheim and Eli Lilly and Company's SGLT2 inhibitor would be the first agent in the class with an indication as an adjunct to diet and exercise for improving glycemic control in children with type 2 diabetes aged 10 years and older.
Read More
STELLAR: Sotatercept Improves Function, Alleviates Disease Burden in Pulmonary Arterial Hypertension
March 6th 2023Data from the phase 3 STELLAR trial indicate adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial's 9 secondary endpoints, including time to death or clinical worsening.
Read More
Mary McGowan, MD: US Clinicians Missing the Mark for High-Risk Hypercholesterolemia
March 6th 2023Mary McGowan, MD, discusses a study she presented examining the overall prevalence of patients with high-risk hypercholesterolemia who fail to meet guideline-recommended goals for LDL-C levels.
Read More
FreeStyle Libre Sensors Cleared for Integration with Automated Insulin Delivery Systems
March 6th 2023The US FDA has granted clearance to the FreeStyle Libre 2 and FreeStyle Libre 3 sensors for integration with automated insulin delivery systems. Abbott, which noted ongoing collaborations with Insulet and Tandem, expects the modified sensors to be available in the US later this year.
Read More
Clyde Yancy, MD: The Prospect of Renal Denervation for Hypertension
March 6th 2023At ACC 2023, HCPLive editorial team sat down with Clyde Yancy, MD, to learn more about his perspective on recent and upcoming advances in cardiovascular care. In this interview, Yancy discusses his perspective on the clinical trial data surrounding renal denervation as a treatment for hypertension.
Read More
Linking Flu Vaccine to Cardiovascular Benefit Could Increase Uptake in Older Adults
March 5th 2023In the largest implementation trial ever conducted, new research from the NUDGE FLU trial suggests informing patients of the potential cardiovascular benefits associated with receipt of the flu vaccine could increase uptake among older adults.
Read More
How Patients Benefit from Growing Intersectionality of Renal and Cardiovascular Diseases
March 4th 2023At ACC.23, our editorial team sat down with a pair of leaders in cardiometabolic health to get their perspective on the growing intersectionality of cardiovascular and chronic kidney disease and how patients have been the beneficiaries of this growing recognition.
Read More
Bempedoic Acid Reduces Risk of MACE by 13%, But Proves No Benefit on Cardiovascular Death
March 4th 2023Results of the CLEAR Outcomes trial suggests adherence to bempedoic acid was associated with a 13% relative reduction in incidence of the trial's primary endpoint of 4-point MACE, but no benefit was observed for risk of cardiovascular death or all-cause mortality in the trial.
Read More
Diabetes Community Reacts to Insulin Price Reduction by Eli Lilly and Company
March 2nd 2023After Eli Lilly and Company announced major reductions in list prices for multiple insulin products, the community rejoiced at the though of taking a major step forward toward equitable access to insulin. Learn more about the reaction from major organizations and those within the field.
Read More
Eli Lilly and Company Announces 70% Reductions in Insulin Prices
March 1st 2023Announced on March 1, Eli Lilly and Company's reduction in insulin product list prices includes non-branded insulin lispro, Rezvoglar, KwikPens, Humulin, and Humalog. The company would also be instituting an out-of-pocket cost cap of $35 for most insulin users.
Read More